Uncategorized
Phase 1/2 trial of gene therapy treatment for X-linked retinitis pigmentosa begins
A phase 1/2 clinical trial of a gene therapy treatment for X-linked retinitis pigmentosa has begun enrolling and dosing subjects, NightstaRx announced in a press release.It is the first kind of trial like this for X-linked retinitis pigmentosa. The gene therapy, AAV-XLRPGR, uses adeno-associated virus to deliver a codon-optimized copy of the retinitis pigmentosa GTPase regulator gene into the cells of the eye, the release said.